Showing 8451-8460 of 19301 results for "".
- Exploring Peptide YY as a Potential Adjunct in Type 2 Diabetes Managementhttps://reachmd.com/news/exploring-peptide-yy-as-a-potential-adjunct-in-type-2-diabetes-management/2484317/Peptide YY is emerging as a validated gut‑hormone adjunct to complement GLP‑1 therapy in type 2 diabetes—improving insulin sensitivity and moderating appetite while avo
- Addressing Parental Anxiety in Pediatric Type 1 Diabetes Managementhttps://reachmd.com/news/addressing-parental-anxiety-in-pediatric-type-1-diabetes-management/2475901/Clinicians often grapple with parental anxiety over hypoglycemia in managing pediatric Type 1 Diabetes, where well-intentioned fear can drive insulin dosing that strays from optimal glycemic t
- Reframing Muscle Preservation in Type 2 Diabetes: Beyond Glycemic Controlhttps://reachmd.com/news/reframing-muscle-preservation-in-type-2-diabetes-beyond-glycemic-control/2475636/Muscle mass reduction is a commonly observed complication in type 2 diabetes, impacting patient health and quality of life. Recent discoveries have unveiled molecular links and metabolic dysfunctions crucial for novel intervention strategies.
- Emerging Roles of Coffee Polyphenols in Type 2 Diabetes Managementhttps://reachmd.com/news/emerging-roles-of-coffee-polyphenols-in-type-2-diabetes-management/2475449/Amidst the search for holistic strategies, emerging data are revealing how coffee’s polyphenolic compounds could enhance glycemic stability and attenuate inflammation in type 2 diabetes management. As primary care physicians and endocr
- Emerging Biomarkers in Type 2 Diabetes: A New Horizon in Early Diagnosishttps://reachmd.com/news/emerging-biomarkers-in-type-2-diabetes-a-new-horizon-in-early-diagnosis/2474920/Recent research suggests that emerging molecular signatures and neuroproteins may improve type 2 diabetes care by offering tools that could help diagnose insulin resistance earlier and assess cognitive decline risk, using markers linked with
- Mitigating CGM Alarm Fatigue in Pediatric Type 1 Diabeteshttps://reachmd.com/news/cgm-alarm-fatigue-pediatric-type-1-diabetes/2484804/Continuous glucose monitoring (CGM) alarm fatigue is emerging as a leading barrier to sustained device use for children with type 1 diabetes and their caregivers. The literature document
- UK Study Advocates Early Screening for Childhood Type 1 Diabetes: Clinical and Program Implicationshttps://reachmd.com/news/uk-study-advocates-early-screening-for-childhood-type-1-diabetes-clinical-and-program-implications/2485410/The ELSA study shows that population screening for childhood type 1 diabetes detects presymptomatic disease a
- Puberty Onset Shifts Forward in Children with Type 1 Diabeteshttps://reachmd.com/news/puberty-onset-shifts-forward-in-children-with-type-1-diabetes/2452636/Puberty in both girls and boys with type 1 diabetes has shifted forward over the last two decades, according to research presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The Hague. Additionally, longer duration of diabetes, bigger waistlines, and
- Lithocholic Acid: A Translational Pathway to Metabolic Health in Type 2 Diabeteshttps://reachmd.com/news/lithocholic-acid-a-translational-pathway-to-metabolic-health-in-type-2-diabetes/2485401/Lithocholic acid (LCA) shows preclinical benefit for glycemic control in a diet‑plus‑streptozotocin mouse model of type 2 diabetes. C57BL/6 mice given daily oral gavage of LCA (50 mg/kg) for four
- Emerging Roles of SGLT2 Inhibitors and GLP-1 RAs in Managing Gout and Type 2 Diabeteshttps://reachmd.com/news/emerging-roles-of-sglt2-inhibitors-and-glp-1-ras-in-managing-gout-and-type-2-diabetes/2475471/Emerging Roles of Sodium‐Glucose Co-Transporter‐2 (SGLT2) Inhibitors and Glucagon‐Like Peptide‐1 Receptor Agonists (GLP-1 RAs) in Managing Gout and Type 2 Diabetes As clinicians face the dual challenge of managing type